Huadong Medicine's Injectable Facial Filler Receives Regulatory Application Acceptance

Stock News06-09

Huadong Medicine Co.,Ltd. (ASX: 000963) has announced a significant regulatory development for one of its key medical aesthetic products.

On June 8, 2026, the company's wholly-owned subsidiary, Xinkeli Aesthetics (Hangzhou) Supply Chain Management Co., Ltd., received an acceptance notice from the National Medical Products Administration (NMPA).

The notice pertains to a Class III medical device application for a new indication of the injectable polycaprolactone microsphere facial filler Ellansé® (Yiyanshi®) S-type.

The new indication sought is for subcutaneous or supraperiosteal implantation in the forehead to improve moderate to severe forehead contour defects.

The successful acceptance of this application for the forehead contour improvement indication marks another major milestone in the product's clinical and registration journey within China.

This development is expected to provide domestic consumers with more facial filling solutions.

It is also anticipated to help the company solidify its first-mover advantage, brand strength, and safety profile in the medical aesthetics sector, further enhancing the product's market potential.

The company stated it will continue to fully advance the registration work for this product in China, aiming to secure approval for the new indication as soon as possible.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1118140430?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-09 16:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118140430","market":"sg","top_or_hot":-1,"title":"Huadong Medicine's Injectable Facial Filler Receives Regulatory Application Acceptance","media":"Stock News","content":"<p><b>Huadong Medicine Co.,Ltd.</b> (<b>ASX: 000963</b>) has announced a significant regulatory development for one of its key medical aesthetic products.<br><br>On June 8, 2026, the company's wholly-owned subsidiary, Xinkeli Aesthetics (Hangzhou) Supply Chain Management Co., Ltd., received an acceptance notice from the National Medical Products Administration (NMPA).<br><br>The notice pertains to a Class III medical device application for a new indication of the injectable polycaprolactone microsphere facial filler Ellansé® (Yiyanshi®) S-type.<br><br>The new indication sought is for subcutaneous or supraperiosteal implantation in the forehead to improve moderate to severe forehead contour defects.<br><br>The successful acceptance of this application for the forehead contour improvement indication marks another major milestone in the product's clinical and registration journey within China.<br><br>This development is expected to provide domestic consumers with more facial filling solutions.<br><br>It is also anticipated to help the company solidify its first-mover advantage, brand strength, and safety profile in the medical aesthetics sector, further enhancing the product's market potential.<br><br>The company stated it will continue to fully advance the registration work for this product in China, aiming to secure approval for the new indication as soon as possible.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Huadong Medicine's Injectable Facial Filler Receives Regulatory Application Acceptance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHuadong Medicine's Injectable Facial Filler Receives Regulatory Application Acceptance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-09 16:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Huadong Medicine Co.,Ltd.</b> (<b>ASX: 000963</b>) has announced a significant regulatory development for one of its key medical aesthetic products.<br><br>On June 8, 2026, the company's wholly-owned subsidiary, Xinkeli Aesthetics (Hangzhou) Supply Chain Management Co., Ltd., received an acceptance notice from the National Medical Products Administration (NMPA).<br><br>The notice pertains to a Class III medical device application for a new indication of the injectable polycaprolactone microsphere facial filler Ellansé® (Yiyanshi®) S-type.<br><br>The new indication sought is for subcutaneous or supraperiosteal implantation in the forehead to improve moderate to severe forehead contour defects.<br><br>The successful acceptance of this application for the forehead contour improvement indication marks another major milestone in the product's clinical and registration journey within China.<br><br>This development is expected to provide domestic consumers with more facial filling solutions.<br><br>It is also anticipated to help the company solidify its first-mover advantage, brand strength, and safety profile in the medical aesthetics sector, further enhancing the product's market potential.<br><br>The company stated it will continue to fully advance the registration work for this product in China, aiming to secure approval for the new indication as soon as possible.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09996","symbol_name":"沛嘉医疗-B","start_time":0,"source_url":"","article_id":"1118140430","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118140430","pubTimestamp":1780993115,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Huadong Medicine Co.,Ltd. (ASX: 000963) has announced a significant regulatory development for one of its key medical aesthetic products.On June 8, 2026, the company's wholly-owned subsidiary,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159883":"医疗器械","09996":"沛嘉医疗-B","BK0187":"一线龙头","BK1583":"高瓴概念","BK0209":"零售","BK1100":"医疗保健设备","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK0132":"高送转概念","BK0183":"MSCI概念","BK0188":"融资融券","BK1574":"生物医药B类股","BK0196":"行业龙头","BK0175":"白马股","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","000963":"华东医药"},"translate_title":"华东医药注射用面部填充剂获监管申请受理","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159883":1,"000963":1,"09996":1},"content_text":"Huadong Medicine Co.,Ltd. (ASX: 000963) has announced a significant regulatory development for one of its key medical aesthetic products.On June 8, 2026, the company's wholly-owned subsidiary, Xinkeli Aesthetics (Hangzhou) Supply Chain Management Co., Ltd., received an acceptance notice from the National Medical Products Administration (NMPA).The notice pertains to a Class III medical device application for a new indication of the injectable polycaprolactone microsphere facial filler Ellansé® (Yiyanshi®) S-type.The new indication sought is for subcutaneous or supraperiosteal implantation in the forehead to improve moderate to severe forehead contour defects.The successful acceptance of this application for the forehead contour improvement indication marks another major milestone in the product's clinical and registration journey within China.This development is expected to provide domestic consumers with more facial filling solutions.It is also anticipated to help the company solidify its first-mover advantage, brand strength, and safety profile in the medical aesthetics sector, further enhancing the product's market potential.The company stated it will continue to fully advance the registration work for this product in China, aiming to secure approval for the new indication as soon as possible.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1118140430","isCrawlerRequest":true}